Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLS PharmaceuticalsFRA:PR80 +6.68%37 Days Inventory is 107.67 as of Dec. 2025, which is 11% below its 10-year median of 121.45. GuruFocus rates FRA:PR80 with a GF Score™ of 37/100 and a GF Value™ of €0.41 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 638 Biotechnology companies, BLS Pharmaceuticals ranks better than 72.73% on this metric.
The historical rank and industry rank for BLS Pharmaceuticals's Days Inventory or its related term are showing as below:
FRA:PR80'
s Days Inventory Range Over the Past 10 Years
Min: 45.68 Med: 121.45 Max: 259.07
Current: 93.55
During the past 13 years, BLS Pharmaceuticals's highest Days Inventory was 259.07. The lowest was 45.68. And the median was 121.45.
FRA:PR80's Days Inventory is ranked better than 72.73% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs FRA:PR80: 93.55
BLS Pharmaceuticals's Days Inventory
increased
from Dec. 2024 (84.10) to Dec. 2025 (107.67).
It might indicate that BLS Pharmaceuticals's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
BLS Pharmaceuticals's Inventory Turnover for the
six
months ended in Dec. 2025 was 1.69.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BLS Pharmaceuticals's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.24.
BLS Pharmaceuticals (FRA:PR80) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
BLS Pharmaceuticals's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BLS Pharmaceuticals's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
BLS Pharmaceuticals Days Inventory Related Terms
BLS Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BLS Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals (FRA:PR80) has a Days Inventory of 107.67 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BLS Pharmaceuticals and its competitors. This is 11% below median its historical median of 121.45. Over the past decade, BLS Pharmaceuticals' Days Inventory has ranged from 45.68 to 259.07. According to the industry distribution chart, BLS Pharmaceuticals ranks #174 out of 638 companies in the Biotechnology industry, placing it in the top 27.3%.
Is BLS Pharmaceuticals' Days Inventory too high?
BLS Pharmaceuticals' current Days Inventory of 107.67 is 11% below median its 10-year median of 121.45. Over the past 10 years, this metric has ranged from a low of 45.68 to a high of 259.07. The Biotechnology industry median Days Inventory is 183.20. BLS Pharmaceuticals' value of 107.67 is 41.2% below this industry median. Based on the distribution chart, BLS Pharmaceuticals ranks #174 out of 638 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BLS Pharmaceuticals has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' Days Inventory compare to ?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #174 out of 638 companies for Days Inventory. This puts BLS Pharmaceuticals in the upper half of its industry. The industry median Days Inventory is 183.20. BLS Pharmaceuticals' value of 107.67 is 41.2% below this benchmark. Historically, BLS Pharmaceuticals' own Days Inventory has ranged from 45.68 to 259.07 over the past decade. While the company's 10-year median is 121.45 vs. the industry median of 183.20, BLS Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLS Pharmaceuticals's current Days Inventory of 107.67 is 41.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BLS Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLS Pharmaceuticals's current Days Inventory is 107.67, which is 11% below median its own 10-year median of 121.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (FRA:PR80) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.41, compared to a current price of €0.58 — trading 41% above its estimated fair value. The current Days Inventory is 107.67, which is 11% below median its 10-year median of 121.45 and 41.2% below the Biotechnology industry median of 183.20. BLS Pharmaceuticals' overall GF Score™ is 37/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For BLS Pharmaceuticals (FRA:PR80), the current Days Inventory is 107.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (FRA:PR80) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of €0.58 is trading 41% above its estimated GF Value™ of €0.41.
GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:PR80:
Days Inventory: 107.67 (11% below median its 10-year median of 121.45)
GF Value™: €0.41 vs. price of €0.58 (41% above fair value)
Industry Position: 41.2% below the Biotechnology median (#174 of 638)
No single metric tells the full story. See the FRA:PR80 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
37GF Score
Get the complete analysis for FRA:PR80
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PR80 has been successfully added to your 
